Tempus AI chief accounting officer sells $13,637 in inventory

Ryan M. Bartolucci, the Chief Accounting Officer at Tempus AI, Inc. (NASDAQ:TEM), an organization presently valued at $6.1 billion, bought 339 shares of Class A Widespread Inventory on December 16. In response to InvestingPro knowledge, the inventory has skilled a 7% decline over the previous week. The shares have been bought at a mean worth of $40.23, leading to a complete transaction worth of $13,637. This transaction was a part of a compulsory sale to cowl tax obligations associated to the vesting of restricted inventory models, as specified by the corporate’s fairness incentive plans. Following this transaction, Bartolucci retained possession of 71,007 shares. InvestingPro evaluation exhibits the corporate maintains sturdy liquidity with a present ratio of two.69, indicating wholesome short-term monetary stability. Subscribers can entry 8 extra key insights about TEM’s monetary well being and market place on the platform.

In different latest information, Tempus AI has been the topic of a number of analyst revisions following their latest earnings report. Piper Sandler notably elevated their worth goal for the corporate from $40 to $70, sustaining a Impartial ranking. This adjustment got here within the wake of Tempus AI’s acquisition of Ambry Genetics, a strategic transfer that guarantees important alternatives in knowledge and functions over time. In the meantime, Stifel downgraded Tempus AI from Purchase to Maintain, however raised their worth goal to $65.

In an analogous vein, Needham raised its worth goal for Tempus AI to $56, whereas sustaining a Purchase ranking. This adjustment was prompted by the corporate’s third-quarter outcomes, which exceeded market expectations. Tempus AI’s CEO, Eric Lefkofsky, has deferred the settlement of roughly 4.47 million restricted inventory models to a interval between January 15, 2025, and March 15, 2025.

In different developments, Tempus AI has entered right into a strategic collaboration with Avacta Therapeutics, aiming to make the most of AI in advancing oncology drug improvement. Avacta will acquire entry to Tempus AI’s complete multimodal datasets, which embrace main tumor samples and related scientific knowledge from over 200,000 sufferers.

Lastly, Tempus AI’s Tempus ECG-AF machine, which makes use of synthetic intelligence to determine sufferers at greater threat of atrial fibrillation/flutter, just lately acquired FDA clearance. These are the latest developments surrounding Tempus AI.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.